{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T16:06:10Z","timestamp":1780934770818,"version":"3.54.1"},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000038","name":"U.S. Food and Drug Administration","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000038","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.jhep.2021.03.021","type":"journal-article","created":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T10:11:12Z","timestamp":1621332672000},"page":"333-341","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["Elevated bilirubin, alkaline phosphatase at onset, and drug metabolism are associated with prolonged recovery from DILI"],"prefix":"10.1016","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2611-3367","authenticated-orcid":false,"given":"Kristin","family":"Ashby","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Gonz\u00e1lez-Jimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismael","family":"Alvarez-Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Isabel","family":"Lucena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ra\u00fal J.","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3924-4830","authenticated-orcid":false,"given":"Guruprasad P.","family":"Aithal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayako","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6453-2351","authenticated-orcid":false,"given":"Minjun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2021.03.021_bib1","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1038\/ajg.2015.283","article-title":"Persistent liver biochemistry abnormalities are more common in older patients and those with cholestatic drug induced liver injury","volume":"110","author":"Fontana","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2021.03.021_bib2","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1007\/s11901-018-0411-0","article-title":"Long-term outcomes after drug-induced liver injury","volume":"17","author":"Hayashi","year":"2018","journal-title":"Curr Hepatol Rep"},{"key":"10.1016\/j.jhep.2021.03.021_bib3","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/j.jhep.2016.05.003","article-title":"Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury","volume":"65","author":"Medina-Caliz","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.03.021_bib4","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.jhep.2008.10.021","article-title":"The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice","volume":"50","author":"Bj\u00f6rnsson","year":"2009","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.03.021_bib5","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2015.03.006","article-title":"Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study","volume":"148","author":"Chalasani","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.03.021_bib6","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2165\/00002018-200932010-00005","article-title":"Drug-induced liver injury network (DILIN) prospective study","volume":"32","author":"Fontana","year":"2009","journal-title":"Drug Saf"},{"key":"10.1016\/j.jhep.2021.03.021_bib7","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/clpt.2011.58","article-title":"Case definition and phenotype standardization in drug-induced liver injury","volume":"89","author":"Aithal","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jhep.2021.03.021_bib8","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.gastro.2005.05.006","article-title":"Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period","volume":"129","author":"Andrade","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.03.021_bib9","series-title":"LiverTox: a website on drug-induced liver injury. Drug-Induced Liver Disease","first-page":"725","author":"Hoofnagle","year":"2013"},{"key":"10.1016\/j.jhep.2021.03.021_bib10","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1002\/hep.21424","article-title":"Outcome of acute idiosyncratic drug-induced liver injury: long-term follow-up in a hepatotoxicity registry","volume":"44","author":"Andrade","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.03.021_bib11","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1365-2036.2007.03355.x","article-title":"Long-term follow-up of patients with mild to moderate drug-induced liver injury","volume":"26","author":"Bj\u00f6rnsson","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2021.03.021_bib12","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/0895-4356(93)90102-7","article-title":"Causality assessment of adverse reactions to drugs\u2014II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge","volume":"46","author":"Benichou","year":"1993","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.jhep.2021.03.021_bib13","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.jhep.2015.04.016","article-title":"Drug-induced liver injury: interactions between drug properties and host factors","volume":"63","author":"Chen","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.03.021_bib14","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/clpt.2013.16","article-title":"The liver toxicity knowledge base: a systems approach to a complex end point","volume":"93","author":"Chen","year":"2013","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jhep.2021.03.021_bib15","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/hep.23317","article-title":"Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events","volume":"51","author":"Lammert","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.03.021_bib16","series-title":"A\u00a0language and environment for statistical computing","year":"2019"},{"key":"10.1016\/j.jhep.2021.03.021_bib17","series-title":"Package \u2018survival\u2019. Survival analysis Published on CRAN","author":"Therneau","year":"2014"},{"key":"10.1016\/j.jhep.2021.03.021_bib18","volume":"vol. 1","author":"Gordon","year":"2018"},{"key":"10.1016\/j.jhep.2021.03.021_bib19","series-title":"An R companion to applied regression (Third)","author":"Fox","year":"2019"},{"key":"10.1016\/j.jhep.2021.03.021_bib20","volume":"vol. 1","author":"Kassambara","year":"2017"},{"key":"10.1016\/j.jhep.2021.03.021_bib21","series-title":"EP03: survival analysis in R companion","author":"Rizopoulos","year":"2020"},{"key":"10.1016\/j.jhep.2021.03.021_bib22","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2014.03.050","article-title":"Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury","volume":"147","author":"Robles\u2013Diaz","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.03.021_bib23","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ddtec.2007.11.003","article-title":"The innovative use of a large-scale industry biomedical consortium to research the genetic basis of drug induced serious adverse events","volume":"4","author":"Holden","year":"2007","journal-title":"Drug Discov Today Tech"},{"key":"10.1016\/j.jhep.2021.03.021_bib24","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1136\/bmj.332.7549.1080","article-title":"The cost of dichotomising continuous variables","volume":"332","author":"Altman","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.jhep.2021.03.021_bib25","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/sim.2331","article-title":"Dichotomizing continuous predictors in multiple regression: a bad idea","volume":"25","author":"Royston","year":"2006","journal-title":"Stat Med"},{"key":"10.1016\/j.jhep.2021.03.021_bib26","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1038\/bjc.2013.34","article-title":"Innovative estimation of survival using log-normal survival modelling on ACCENT database","volume":"108","author":"Chapman","year":"2013","journal-title":"Br J Canc"},{"key":"10.1016\/j.jhep.2021.03.021_bib27","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1111\/hepr.13435","article-title":"Prolonged interval of total bilirubin decline is an early independent predictive factor of chronic persistent drug-induced liver injury","volume":"50","author":"Zhu","year":"2020","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2021.03.021_bib28","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/gut.44.5.731","article-title":"The natural history of histologically proved drug induced liver disease","volume":"44","author":"Aithal","year":"1999","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2021.03.021_bib29","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2014.03.045","article-title":"Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset","volume":"147","author":"Fontana","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.03.021_bib30","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/liv.13952","article-title":"The influence of drug properties and host factors on delayed onset of symptoms in drug-induced liver injury","volume":"39","author":"Gonzalez-Jimenez","year":"2019","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2021.03.021_bib31","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1016\/j.cgh.2013.12.016","article-title":"Relationship between characteristics of medications and drug-induced liver disease phenotype and outcome","volume":"12","author":"Vuppalanchi","year":"2014","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.03.021_bib32","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1002\/hep.26208","article-title":"High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury","volume":"58","author":"Chen","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.03.021_bib33","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.3390\/ijms18071335","article-title":"Associations of drug lipophilicity and extent of metabolism with drug-induced liver injury","volume":"18","author":"McEuen","year":"2017","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jhep.2021.03.021_bib34","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0041-008X(03)00368-5","article-title":"Diclofenac-induced liver injury: a paradigm of idiosyncratic drug toxicity","volume":"192","author":"Boelsterli","year":"2003","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.jhep.2021.03.021_bib35","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1093\/toxsci\/kfaa124","article-title":"Identification of flucloxacillin-haptenated HLA-B\u2217 57: 01 ligands: evidence of antigen processing and presentation","volume":"177","author":"Waddington","year":"2020","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.jhep.2021.03.021_bib36","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1398-9995.1998.tb03778.x","article-title":"Allergy to antibiotics: T-cell recognition of amoxicillin is HLA-DR restricted and does not require antigen processing","volume":"53","author":"Horton","year":"1998","journal-title":"Allergy"},{"key":"10.1016\/j.jhep.2021.03.021_bib37","first-page":"819","article-title":"Nitrofurantoin-induced hepatotoxicity mediated by CD8 T cells","volume":"93","author":"Kelly","year":"1998","journal-title":"Am J Gastroenterol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827821002245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827821002245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:43:13Z","timestamp":1759174993000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827821002245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S0168827821002245"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2021.03.021","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Elevated bilirubin, alkaline phosphatase at onset, and drug metabolism are associated with prolonged recovery from DILI","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2021.03.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}